Tumor News and Research

RSS

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.

13 May 2015

Scientists discover way to regrow bone tissue using proteins produced by stem cells

Scientists have discovered a way to regrow bone tissue using the protein signals produced by stem cells. This technology could help treat victims who have experienced major trauma to a limb, like soldiers wounded in combat or casualties of a natural disaster. The new method improves on older therapies by providing a sustainable source for fresh tissue and reducing the risk of tumor formation that can arise with stem cell transplants.

13 May 2015

Researchers develop new tool to identify common genetic anomalies in cancer

Researchers from the University of Michigan Comprehensive Cancer Center and Thermo Fisher Scientific have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples.

13 May 2015

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

Childhood cancer survivors more likely to be obese than healthy peers

Childhood cancer survivors - especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids - are 14 percent more likely to be obese than their healthy peers.

12 May 2015

Researchers identify three genes involved in choroid plexus carcinoma

Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Cancer Cell.

12 May 2015

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.

12 May 2015

DNMT1 gene essential to maintain breast and cancer stem cells

The gene and hormone soup that enables women to breastfeed their newborns also can be a recipe for breast cancer, particularly when the first pregnancy is after age 30.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Experimental gene therapy holds promise against metastatic prostate cancer

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.

12 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

Walnut-enriched diet may slow colorectal tumor growth

A new animal study from Beth Israel Deaconess Medical Center, Harvard Medical School, led by Dr. Christos Mantzoros, indicates that a diet containing walnuts may slow colorectal tumor growth by causing beneficial changes in cancer genes.

11 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

The Project Data Sphere® initiative achieves 1st year milestones

Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives...

11 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options.

11 May 2015

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche today announced that the U.S. Food and Drug Administration has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer (mCRC) patients and aid clinicians in determining a therapeutic path for them.

11 May 2015

Study finds link between PTSD and accelerated aging

In recent years, public health concerns about post-traumatic stress disorder (PTSD) have risen significantly, driven in part by affected military veterans returning from conflicts in the Middle East and elsewhere. PTSD is associated with number of psychological maladies, among them chronic depression, anger, insomnia, eating disorders and substance abuse.

10 May 2015

Study sheds light on developing more targeted therapies against medulloblastoma

St. Jude Children's Research Hospital scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor.

10 May 2015

Tumor News and Research

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Scientists discover way to regrow bone tissue using proteins produced by stem cells

Researchers develop new tool to identify common genetic anomalies in cancer

Research paves way for development of individualized immunotherapy for treating cancer

Childhood cancer survivors more likely to be obese than healthy peers

Researchers identify three genes involved in choroid plexus carcinoma

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

DNMT1 gene essential to maintain breast and cancer stem cells

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Experimental gene therapy holds promise against metastatic prostate cancer

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Walnut-enriched diet may slow colorectal tumor growth

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

The Project Data Sphere® initiative achieves 1st year milestones

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Study finds link between PTSD and accelerated aging

Study sheds light on developing more targeted therapies against medulloblastoma

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News